Floatz logo

Inno-206

Pheochromocytoma

European Organisation for Research and Treatment of Cancer - EORTCPhase 3Dormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Pheochromocytoma cohort.

Asset / SponsorPhaseRating
Ifosfamide
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3BB
FILGRASTIM
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Ottawa Regional Cancer Centre
Phase 2B
TAMOXIFEN
Ottawa Regional Cancer Centre
Phase 2B
Fostamatinib Disodium
National Cancer Institute (NCI)
Phase 2B

View all 22 →

Same molecule, other indications

Inno-206 is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
Recurrent Adult Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →